Form 144 - Report of proposed sale of securities:
SEC Accession No. 0001628280-25-048931
Filing Date
2025-11-04
Accepted
2025-11-04 16:48:41
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html 144  
1 primary_doc.xml 144 3045
2 EX-99 table_iix20251104.pdf EX-99 29033
  Complete submission text file 0001628280-25-048931.txt   44892
Mailing Address 399 BOYLSTON STREET SUITE 1100 BOSTON MA 02142
Business Address 399 BOYLSTON STREET SUITE 1100 BOSTON MA 02142 617-425-9200
UBS Oncology Impact Fund L.P. (Reporting) CIK: 0001691428 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 144

Mailing Address 200 TALCOTT AVENUE 2ND FLOOR WATERTOWN MA 02472
Business Address 200 TALCOTT AVENUE 2ND FLOOR WATERTOWN MA 02472 617-952-0555
Werewolf Therapeutics, Inc. (Subject) CIK: 0001785530 (see all company filings)

EIN.: 823523180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 144 | Act: 33 | File No.: 001-40366 | Film No.: 251450256
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)